癌症医治的新时期-js999555.com-4136金沙网站

一名晚期结肠癌病人,正在手术和化疗无效的状况下,正在St.Jude Crosson癌症研究中心,经由免疫疗法和靶向医治,与得了胜利,病人曾经存活两年多了,并且现在状态很好,那是医学史上的事业。那给大夫和病人更大的自信心,正在更多癌症医治上发明事业。

澳门金沙线上娱乐

2013年,64岁的Don Kwart(睹下图)做肠镜发明II期结肠癌,马上做了却肠癌切除术,随后停止了6个月的化疗。以后影象学搜检和血液化验证实医治有用。然则几个月后,肿瘤复发了而且发作了远处转移,随后又停止化疗,最先借有点回响反映,肿块有点缩小,然则很快便无效了。

5hkcom金沙登入

一般来说,手术和化疗失利了,也便预示着有用的医治计划闭幕了,病人一样平常只能存活6到8个月。

美国St. Jude Crosson癌症研究所David Park博士,对Don的癌症停止基因剖析,勇敢天提出新的医治战略,接纳Keytruda(派姆单抗)停止试验性免疫医治。

js999555.com
David J. Park, MD, Hematology andOncology (Board Certified)

然则事先美国FDA只核准Keytruda用于医治恶性黑色素瘤和肺癌。然则,Park博士以为,新近的材料曾经显现出Keytruda能医治像Don如许结肠癌的曙光,由于他们具有雷同的基因符号物。

Park博士取Keytruda厂家联络,期望厂家赐与病人怜悯,赞成立刻供应Keytruda,让病人停止视察性医治。

Don险些立刻对免疫疗法发作回响反映,医治异常有用。“对我来讲,那是一个奇异的药物。” Don道:“我比以往几年觉得更好。我应该是Keytruda医治异常有用的典范代表。”

从Keytruda医治到如今,曾经两年多了,Don的状况非常好。您要找他,能够去棒球场找到他,他儿子是棒球队的先发投手,他一向去看他儿子的竞赛。

Don接管Keytruda医治后的一年,美国FDA才核准了Keytruda能够用于缺少错配修复功用的任何癌症,那是癌症医治史上照样头一次。

“医治癌症,基于肿瘤基因或份子学特性,而不是肿瘤少正在那里-----那是一种典范的形式改动。”Park博士注释讲。客岁,免疫医治和靶向医治的数目翻了一倍,并且医治的范畴比以往更广。只要找到癌症的致命缺点,我们便能够将胜利的可能性最大化,同时制止无效的医治。

正在Crosson癌症研究中心,具有天下一流的肿瘤份子检测装备,对结肠癌、乳腺癌、肺癌、黑色素瘤、头颈肿瘤、胰腺癌和其他癌症包孕复发癌症,停止通例的份子检测。

“免疫医治和靶向医治,让癌症医治靠近于治愈程度。”Park博士道,St. Jude曾经对十几种癌症展开了基因免疫疗法或/和靶向医治结合等临床试验。St. Jude Crosson癌症研究所,作为精准肿瘤学同盟成员,曾经到场了几个全国性的临床研讨项目。

信息来自:

http://www.stjudemedicalcenter.org/about-us/newsroom-and-highlights/highlights/2018/a-new-era-in-cancer-treatment/,文章经由编译整顿。

A NEW ERA INC ANCER TREATMENT-澳门金沙线上娱乐-js999555.com

Targeted Therapies Bring Dramatic New Successes

Using the body’s own immune system to destroy cancer has been the holy grail for cancer researchers for decades. At the St. Jude Crosson Cancer Institute, the promise of immunotherapies and targeted therapies—designed to help the immune system recognize and kill cancer cells—has moved from the lab to the bedside, with often remarkable outcomes.

Just ask Don Kwart.

In 2013, a colonoscopy revealed the 64-year-old had Stage II colon cancer, and surgery to remove the diseased colon tissue was followed by six months of chemotherapy. While imaging and blood work showed the treatment was successful, several months later, the aggressive cancer had returned and metastasized. More chemotherapy over the next year at first slowed the cancer’s growth—and then simply s ped working.

In the past, the failure of surgery and chemotherapy would signal the end of available treatment options. But after genetically profiling Don’s cancer, David Park, MD, Medical Director of Oncology Services and a board-certified oncologist with St. Jude Heritage Medical Group, offered a new strategy: an experimental immunotherapy, called Keytruda.

Keytruda targets activity within a cancer cell, activity which permits the cancer to protect itself from an immune system response. By “uncloaking” the cancer cells, Keytruda allows the immune system’s T-cells to complete their search-and-destroy mission. The FDA had approved it for melanoma and lung cancer at that time, but not for colon cancer. However, Dr. Park believed the early data looked promising for cancers with the same genetic markers as Don’s.

He arranged “compassionate access” with the pharmaceutical company, allowing Don to immediately begin receiving the investigational therapy. Don responded to the immunotherapy almost immediately. “For me, it’s been a miracle drug,” says the father of five and grandfather of two. “I feel better than I have in years. I should be the ‘poster child’ for Keytruda.”

Once chemotherapy s s working, life expectancy is typically six to eight months. For Don, that milestone was over two years ago. And if you want to talk to him about it, you’ll need to catch him between baseball games: Don’s son is one of the high school team’s starting pitchers and Don never misses an inning.

Over a year after Don began therapy, the FDA approved the use of Keytruda for any tumor with the genetic feature of deficient

mismatch repair (a marker in Don’s cancer)—a first in the history of cancer therapy.

“Treating tumors based on their genetic or molecular characteristics—instead of where they are located—is a paradigm change,” explains Dr. Park, who says the number of immunotherapies and targeted therapies doubled last year with many more in the pipeline. “By finding the Achilles’ heel of a tumor, we can maximize the likelihood of success while avoiding therapies that are unlikely to work.”

At the Crosson Cancer Institute, state-of-the-art molecular profiling of tumors is now routine for patients with colon, breast, lung, melanoma, head and neck, pancreas and other cancers—as well as for patients who have experienced a recurrence.

“Immunotherapies and targeted therapies are moving us much closer to a cure,” says Dr. Park, explaining that clinical trials involving immunotherapies alone, or combined with other treatments, are underway at St. Jude for nearly a dozen different cancers. As the hospital’s board-certified oncologists aggressively pursue new breakthroughs, St. Jude has participated in several national research trials.

The Crosson Cancer Institute is a member of Precision Oncology Alliance, working with other nationally-recognized cancer centers to advance tumor profiling and research to better diagnose, treat and bring personalized precision medicine to all cancer patients.